ClinicalTrials.gg
CompletedNCT00643227Updated Mar 26, 2008

A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Clarithromycin Extended Release for the Treatment of Pneumonia in Adult Patients

A Phase 3 interventional study of clarithromycin extended release (ER) and azithromycin SR in Pneumonia, sponsored by Pfizer. Completed at 72 sites in 7 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2008-03-26.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
504
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing azithromycin in Pneumonia — 1 open to participants now, 2 under way, 1 of them phase 3. Azithromycin · Pneumonia.

Enrollment
5th of 13
504 · median 151
Started
2003
with 3 others
Phase 3
5 of 13
1 open now
Registered
6th of 13
by date
Lead sponsor
3 of 13
Pfizer

Among the 13 studies testing azithromycin in Pneumonia, this one is the 5th largest by enrollment, is one of 4 that started in 2003, is one of 5 in phase 3, and was the 6th registered.

Pneumonia

1,568 studies on the registry are indexed under Pneumonia; 267 are open to participants now.

Browse Pneumonia studies →

Open to participants now

1 of the 13 studies testing azithromycin in Pneumonia is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About azithromycin

Azithromycin: first FDA approval 1991 (ZITHROMAX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 158 Pneumonia studies recruiting now, 84 (53%) set no upper age limit and 48 (30%) stop at 75 or younger; 41 take children under 18; 24 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing azithromycin in Pneumonia, or all of them as a file.
02

Study summary

The study was performed to confirm that a single, 2.0 g oral dose of azithromycin sustained release (SR) at least as effective as 7 days of clarithromycin extended release (ER), 1.0 g by mouth once daily, when used to treat adults with mild to moderate community acquired pneumonia (CAP), and that both treatments were safe.

03

Conditions studied

  • Pneumonia

Browse trials for

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Outpatients with a diagnosis of pneumonia, as demonstrated by a productive cough and at least 2 of the following signs and symptoms: rales and/or evidence of pulmonary consolidation; dyspnea or tachypnea; elevated body temperature; or elevated total peripheral white blood cell count (WBC >10,000/mm3) or greater than 15% immature neutrophils were included. Patients were to have a chest radiograph demonstrating evidence of a new infiltrate or consolidation, and a Modified Fine Risk score of ≤ 70 (Fine Class I and II).

Exclusion criteria

Exclusion Criteria:

Patients who were treated with any systemic antibiotic of greater than 1 dose or 1 combination dose (such as cephalosporin and macrolide) within the previous 7 days, or the likelihood of receiving other systemic antibiotics during participation in the study; were hospitalized in the previous 14 days or had an infection acquired in the hospital, and who were residents of a long-term care facility were excluded.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
504 participants (actual)

Study arms

  • Experimental
    1

    Drug: clarithromycin extended release (ER)

  • Experimental
    2

    Drug: azithromycin SR

Interventions

06

What researchers measure

Primary outcomes

  1. sponsor assessment of clinical response (clinical cure rate) in the Clinical Per Protocol population

    Time frame: Test of Cure (TOC) visit (Day 14-21)

Secondary outcomes

  1. bacteriologic response (eradication rate) in the Bacteriological Per Protocol population

    Time frame: TOC visit

  2. investigator assessment of clinical response in the Clinical Per Protocol population

    Time frame: TOC visit

  3. sponsor assessment of clinical response by baseline pathogen

    Time frame: End of Treatment (EOT) visit (Day 8-11) and TOC visit

  4. sponsor assessment of clinical response in the non-primary population

    Time frame: EOT visit and TOC visit

  5. sponsor assessment of clinical responses in the Clinical Per Protocol population

    Time frame: EOT visit and Long-Term Follow-Up (LTFU) visit (Day 28-35)

  6. susceptibilities of baseline pathogens

    Time frame: Study endpoint

  7. adverse events

    Time frame: Continuous

  8. vital signs

    Time frame: Baseline, On-Treatment (OT) visit (Day 3-5), and TOC visit

  9. physical examination

    Time frame: Baseline

  10. clinical laboratory assessments (blood chemistry and hematology)

    Time frame: Baseline and TOC visit

07

Study locations

72 sites
  • Pfizer Investigational Site
    Birmingham, Alabama 35215, United States
  • Pfizer Investigational Site
    Birmingham, Alabama 35242, United States
  • Pfizer Investigational Site
    Haleyville, Alabama 35565, United States
  • Pfizer Investigational Site
    Montgomery, Alabama 36106, United States
  • Pfizer Investigational Site
    Montgomery, Alabama 36109, United States
  • Pfizer Investigational Site
    Tallassee, Alabama 36078, United States
  • Pfizer Investigational Site
    Mesa, Arizona 85201, United States
  • Pfizer Investigational Site
    Phoenix, Arizona 85014, United States
  • Pfizer Investigational Site
    Tempe, Arizona 85282, United States
  • Pfizer Investigational Site
    La Jolla, California 92037, United States
  • Pfizer Investigational Site
    San Diego, California 92128, United States
  • Pfizer Investigational Site
    Orlando, Florida 32806, United States
  • Pfizer Investigational Site
    Boise, Idaho 83703, United States
  • Pfizer Investigational Site
    Boise, Idaho 83704, United States
  • Pfizer Investigational Site
    Boise, Idaho 83706, United States
  • Pfizer Investigational Site
    Boise, Idaho 83709, United States
  • Pfizer Investigational Site
    Boise, Idaho 83713, United States
  • Pfizer Investigational Site
    Meridian, Idaho 83642, United States
  • Pfizer Investigational Site
    Nampa, Idaho 83651, United States
  • Pfizer Investigational Site
    Chalmette, Louisiana 70043, United States
  • Pfizer Investigational Site
    New Orleans, Louisiana 70112, United States
  • Pfizer Investigational Site
    New Orleans, Louisiana 70128, United States
  • Pfizer Investigational Site
    Butte, Montana 59701, United States
  • Pfizer Investigational Site
    Holmdel, New Jersey 07733, United States
  • Pfizer Investigational Site
    Clemmons, North Carolina 27012, United States
  • Pfizer Investigational Site
    Salisbury, North Carolina 28144, United States
  • Pfizer Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • Pfizer Investigational Site
    Charleston, South Carolina 29406, United States
  • Pfizer Investigational Site
    Summerville, South Carolina 29485, United States
  • Pfizer Investigational Site
    Milan, Tennessee 38358, United States
  • Pfizer Investigational Site
    Salt Lake City, Utah 84102, United States
  • Pfizer Investigational Site
    Salt Lake City, Utah 84109, United States
  • Pfizer Investigational Site
    Salt Lake City, Utah 84121, United States
  • Pfizer Investigational Site
    Taylorsville, Utah 84118, United States
  • Pfizer Investigational Site
    West Jordan, Utah 84088, United States
  • Pfizer Investigational Site
    Casper, Wyoming 82601, United States
  • Pfizer Investigational Site
    Tandil, Buenos Aires B7000AXD, Argentina
  • Pfizer Investigational Site
    Buenos Aires, 1427, Argentina
  • Pfizer Investigational Site
    Buenos Aires, C1120AAF, Argentina
  • Pfizer Investigational Site
    Buenos Aires, C1272AAA, Argentina
  • Pfizer Investigational Site
    Buenos Aires, C1282AFQ, Argentina
  • Pfizer Investigational Site
    Edmonton, Alberta T5A 4L8, Canada
  • Pfizer Investigational Site
    Coquitlam, British Columbia V3K 3P4, Canada
  • Pfizer Investigational Site
    St-John's, Newfoundland and Labrador A1E 2E2, Canada
  • Pfizer Investigational Site
    Toronto, Ontario M9W 4L6, Canada
  • Pfizer Investigational Site
    Chicoutimi, Quebec G7H 5H6, Canada
  • Pfizer Investigational Site
    Drummondville, Quebec J2B 1H8, Canada
  • Pfizer Investigational Site
    Granby, Quebec J2G 8Z9, Canada
  • Pfizer Investigational Site
    Longueuil, Quebec J4N 1E1, Canada
  • Pfizer Investigational Site
    Pointe Claire, Quebec H9R 4S3, Canada
  • Pfizer Investigational Site
    St Jerome, Quebec J7Z 5T3, Canada
  • Pfizer Investigational Site
    Ste-Foy, Quebec G1V 4G5, Canada
  • Pfizer Investigational Site
    Saskatoon, Saskatchewan S7K 3H3, Canada
  • Pfizer Investigational Site
    Tallinn, 10617, Estonia
  • Pfizer Investigational Site
    Tallinn, 13419, Estonia
  • Pfizer Investigational Site
    Tallinn, 13619, Estonia
  • Pfizer Investigational Site
    Tartu, 51014, Estonia
  • Pfizer Investigational Site
    Hyderabad, Andhra Pradesh 500 033, India
  • Pfizer Investigational Site
    Bangalore, Karnataka 560 034, India
  • Pfizer Investigational Site
    Elamakkara, Cochin, Kerala 682 026, India
  • Pfizer Investigational Site
    Pune, Maharashtra 411 053, India
  • Pfizer Investigational Site
    Ludhiana, Punjab 141 001, India
  • Pfizer Investigational Site
    Coimbatore, Tamil Nadu 641 022, India
  • Pfizer Investigational Site
    Kaunas, LT-3000, Lithuania
  • Pfizer Investigational Site
    Vilnius, LT-2010, Lithuania
  • Pfizer Investigational Site
    Moscow, 105077, Russian Federation
  • Pfizer Investigational Site
    Moscow, 105229, Russian Federation
  • Pfizer Investigational Site
    Moscow, 107066, Russian Federation
  • Pfizer Investigational Site
    Moscow, 119048, Russian Federation
  • Pfizer Investigational Site
    Moscow, Russian Federation
  • Pfizer Investigational Site
    Smolensk, 214019, Russian Federation
  • Pfizer Investigational Site
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2003 and a completion of Mar 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2008
First posted
Mar 26, 2008
Start
Jan 2003
CompletionActual
Mar 2004
Last update
Mar 26, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00643227
Lead sponsor
Pfizer
First posted
Mar 26, 2008
Start date
Jan 2003
Completion
Mar 2004
Last update
Mar 26, 2008

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Clarithromycin · Azithromycin

Start the discussion